AI Article Synopsis
Article Abstract
15-Deoxy-∆12,14-prostaglandin J2 (15d‑PGJ2) is a natural agonist of peroxisome proliferator-activated receptor γ (PPARγ) that displays anticancer activity. Various studies have indicated that the effects of 15d‑PGJ2 are due to both PPARγ-dependent and -independent mechanisms. In the present study, we examined the effects of a biotinylated form of 15d‑PGJ2 (b‑15d‑PGJ2) on hormone-dependent MCF‑7 and triple‑negative MDA‑MB‑231 breast cancer cell lines. b‑15d‑PGJ2 inhibited cell proliferation more efficiently than 15d‑PGJ2 or the synthetic PPARγ agonist, efatutazone. b‑15d‑PGJ2 was also more potent than its non-biotinylated counterpart in inducing apoptosis. We then analyzed the mechanisms underlying this improved efficiency. It was found not to be the result of biotin receptor-mediated increased incorporation, since free biotin in the culture medium did not decrease the anti-proliferative activity of b‑15d‑PGJ2 in competition assays. Of note, b‑15d‑PGJ2 displayed an improved PPARγ agonist activity, as measured by transactivation experiments. Molecular docking analyses revealed a similar insertion of b‑15d‑PGJ2 and 15d‑PGJ2 into the ligand binding domain of PPARγ via a covalent bond with Cys285. Finally, PPARγ silencing markedly decreased the cleavage of the apoptotic markers, poly(ADP-ribose) polymerase 1 (PARP‑1) and caspase‑7, that usually occurs following b‑15d‑PGJ2 treatment. Taken together, our data indicate that biotinylation enhances the anti-proliferative and pro-apoptotic activity of 15d‑PGJ2, and that this effect is partly mediated via a PPARγ-dependent pathway. These results may aid in the development of novel therapeutic strategies for breast cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/ijo.2018.4338 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural epigallocatechin-3-gallocarboxylate nanoformulation loaded doxorubicin to construct a novel and low cardiotoxicity chemotherapeutic drug for high-efficiency breast cancer therapy.
J Nanobiotechnology
December 2024
School of Life and Environmental Sciences, Shaoxing University, Shaoxing, 312000, Zhejiang, China.
Anthracycline doxorubicin (DOX) remains the first-line chemotherapeutic drug for the efficient treatment of breast cancer, but its severe cardiotoxicity limits its long-term application in clinical tumor chemotherapy. Until now, the pathogenesis mechanism of DOX-induced cardiotoxicity (DIC) is still not fully understood. According to current studies, the oxidative stress caused by the imbalance of reactive oxygen species (ROS) and reactive nitrogen species (RNS) production and mitochondrial dysfunction in myocardial cells are closely related to DIC.
View Article and Find Full Text PDFDevelopment and preliminary validation of the Dietary Self-management Behavior Questionnaire (DSMBQ) for breast cancer patients during chemotherapy: three rounds of survey.
BMC Public Health
December 2024
Department of Health Statistics, School of Public Health, The Fourth Military Medical University, Xi'an, 710032, China.
Background: Adverse effects during chemotherapy severely impact the daily diet of breast cancer (BC) patients. Engaging in dietary self-management is crucial for healthy lifestyle and recovery. This study aims to create the Dietary Self-management Behavior Questionnaire (DSMBQ) and preliminarily validate its reliability, validity, and discriminative ability for BC patients undergoing chemotherapy.
View Article and Find Full Text PDFAripiprazole-loaded niosome/chitosan-gold nanoparticles for breast cancer chemo-photo therapy.
BMC Biotechnol
December 2024
Department of Microbiology, Faculty of Veterinary and Agriculture, Islamic Azad University, Shabestar Branch, Shabestar, Iran.
Introduction: Breast cancer, a formidable global health challenge for women, necessitates innovative therapeutic strategies with enhanced efficacy and minimal side effects. Aripiprazole (ARI), a widely used schizophrenia medication, exhibits promising potential in the treatment of breast cancer. As cancer therapy evolves towards a combination approach, multimodal nano-based delivery systems, such as ARI-loaded niosomes (NIOs) combined with Chitosan-Au nanoparticles for chemo-photothermal therapy, show promise over traditional chemotherapy alone by enhancing targeted efficacy and minimizing side effects.
View Article and Find Full Text PDFUnresectable stage III NSCLC is now treated with chemoradiation (CRT) followed by immune checkpoint inhibitors (ICI). Pneumonitis, a common CRT complication, has heightened risk with ICI, potentially causing severe outcomes. Currently, there are no biomarkers to predict pneumonitis risk or differentiate between radiation-induced pneumonitis (RTP) and ICI-induced pneumonitis (IIP).
View Article and Find Full Text PDFThe Train: A Supply of Inspiration for Delivering High-Quality Cancer Care.
Ann Surg Oncol
December 2024
Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Background: The past 10 years have convincingly shown that the TRAIN-studies, with their starting point in Antoni van Leeuwenhoek (Amsterdam), have proved their significance for breast cancer patients with stage II or III human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The main aim of these studies is to maximize a positive, clinically relevant outcome with the least burdensome neoadjuvant systemic treatment option after which surgery and systemic treatment (in accordance with the current oncology guidelines) is provided.
Rationale And Conclusions: The breast cancer train studies give rise to plenty of ideas for optimization of treatment in oncology, which is in the best interest of the patient, the treating doctor or caregiver, and society.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!